Record Revenue Driven by Key Segments

Godrej Agrovet Limited (GAVL) has reported a dynamic operational year, achieving record consolidated revenue of ₹10,233 crore for fiscal year 2026. This performance highlights distinct results across its various business units, with some segments showing strong growth while others face significant challenges.

Oil Palm and Animal Nutrition Drive Growth

The Oil Palm business was a key performer, with segment profit climbing nearly 68% to ₹384 crore. This was driven by double-digit volume growth, better oil extraction rates, and a substantial 46.7% increase in palm kernel oil prices to ₹2,14,754 per metric tonne. The Animal Nutrition segment, GAVL's largest revenue contributor, posted a 19.3% rise in segment profit to ₹347 crore, fueled by 12% overall volume growth, especially in cattle feed. These gains align with rising demand for animal-based protein and dairy in India, supporting the animal feed sector.

Challenges in Crop Care and Dairy

The agricultural inputs division presented a contrasting picture. The Crop Care business saw a steep 27.2% decline in segment profit to ₹224 crore. This downturn was due to factors including adverse weather affecting crop cycles, reduced planting acreage, and disruptions from regulatory changes, made worse by an oversupply in distribution channels. Creamline Dairy also faced pressure, with EBITDA falling 33% to ₹53 crore as rising milk procurement costs outpaced revenue growth.

The underperformance in Crop Care raises concerns. Persistent bad weather and regulatory changes suggest this division may face extended challenges. The agrochemical sector is highly competitive and subject to evolving environmental rules and patent expirations. GAVL has historically found it difficult to compete with global giants like UPL, which has a wider product range and greater scale. The dairy segment's sensitivity to rising milk prices highlights the difficulty in passing these costs to consumers in a price-sensitive market.

Astec LifeSciences and Operational Strength

Subsidiary Astec LifeSciences demonstrated a significant turnaround, moving from an EBITDA loss of ₹61 crore in FY25 to near break-even in FY26, with revenues climbing 17.5% to ₹448 crore. This operational improvement is a positive step, potentially helping to offset losses in other segments.

Godrej Agrovet's P/E ratio of approximately 55x as of May 1, 2026, is a premium compared to peers like UPL (around 25x) and Coromandel International (around 35x), indicating market expectations for continued high growth. Historically, GAVL's stock has reacted cautiously to results showing segment weaknesses, often recovering if operational improvements are evident.

Analyst Views and Operational Focus

Recent analyst assessments for Godrej Agrovet show a mixed outlook, with price targets generally ranging between ₹980 and ₹1,050. Analysts acknowledge the strong growth in Oil Palm and Animal Nutrition and the turnaround at Astec LifeSciences. However, caution remains regarding the Crop Care segment's recovery and competitive pressures in the dairy business.

The company's ability to manage working capital effectively, reducing it to 25 days from 39 days, and improving return on capital employed to 20%, points to operational efficiency gains. The market will be watching for management's strategies to address Crop Care issues and maintain momentum in its high-growth divisions.